StocksFundsScreenerSectorsWatchlists
KRYS

KRYS - Krystal Biotech Inc Stock Price, Fair Value and News

176.53USD-0.67 (-0.38%)Delayed as of 28 Mar 2024, 10:58 am ET

Market Summary

KRYS
USD176.53-0.67
Delayedas of 28 Mar 2024, 10:58 am
-0.38%

KRYS Alerts

  • 3 major insider sales recently.
  • Big jump in Earnings (Y/Y)

KRYS Stock Price

View Fullscreen

KRYS RSI Chart

KRYS Valuation

Market Cap

5.0B

Price/Earnings (Trailing)

458.6

Price/Sales (Trailing)

98.89

EV/EBITDA

260.11

Price/Free Cashflow

-49.83

KRYS Price/Sales (Trailing)

KRYS Profitability

EBT Margin

25.44%

Return on Equity

1.4%

Return on Assets

1.34%

Free Cashflow Yield

-2.01%

KRYS Fundamentals

KRYS Revenue

Revenue (TTM)

50.7M

Rev. Growth (Qtr)

392.55%

KRYS Earnings

Earnings (TTM)

10.9M

Earnings Growth (Yr)

127.12%

Earnings Growth (Qtr)

-89.24%

Breaking Down KRYS Revenue

52 Week Range

77.10177.53
(Low)(High)

Last 7 days

-3.3%

Last 30 days

47.3%

Last 90 days

35.1%

Trailing 12 Months

136.4%

How does KRYS drawdown profile look like?

KRYS Financial Health

Current Ratio

17.76

KRYS Investor Care

Shares Dilution (1Y)

9.82%

Diluted EPS (TTM)

0.24

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202300050.7M
20220000
20210000
20180000

Tracking the Latest Insider Buys and Sells of Krystal Biotech Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Mar 11, 2024
krishnan suma
sold
-4,274,040
170
-25,000
president, r&d
Mar 11, 2024
krishnan krish s
sold
-4,274,040
170
-25,000
president and ceo
Mar 11, 2024
krishnan krish s
sold
-4,273,680
170
-25,000
president and ceo
Mar 11, 2024
krishnan suma
sold
-4,273,680
170
-25,000
president, r&d
Feb 28, 2024
krishnan krish s
acquired
-
-
7,500
president and ceo
Feb 28, 2024
krishnan krish s
sold (taxes)
-566,051
163
-3,471
president and ceo
Feb 28, 2024
romano kathryn
acquired
470,270
63.55
7,400
chief accounting officer
Feb 28, 2024
krishnan suma
acquired
-
-
7,500
president, r&d
Feb 28, 2024
romano kathryn
sold (taxes)
-377,367
163
-2,314
chief accounting officer
Feb 28, 2024
krishnan suma
sold (taxes)
-943,418
163
-5,785
president, r&d

1–10 of 50

Which funds bought or sold KRYS recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Mar 22, 2024
PNC FINANCIAL SERVICES GROUP, INC.
reduced
-23.81
-9,021
39,699
-%
Mar 11, 2024
VANGUARD GROUP INC
added
1.48
23,765,700
302,182,000
0.01%
Mar 01, 2024
GOLDMAN SACHS GROUP INC
added
147
35,200,600
56,584,500
-%
Feb 28, 2024
AMERICAN INTERNATIONAL GROUP, INC.
reduced
-0.4
81,609
1,332,900
-%
Feb 26, 2024
Privium Fund Management B.V.
added
26.87
221,626
825,986
0.23%
Feb 20, 2024
EVENTIDE ASSET MANAGEMENT, LLC
new
-
16,932,300
16,932,300
0.28%
Feb 16, 2024
PRICE T ROWE ASSOCIATES INC /MD/
added
66.8
23,299,000
53,020,000
0.01%
Feb 15, 2024
Virtus ETF Advisers LLC
added
3.92
9,896
98,752
0.06%
Feb 15, 2024
JANE STREET GROUP, LLC
reduced
-32.62
-2,434,950
6,279,670
-%
Feb 15, 2024
BARCLAYS PLC
added
62.4
3,380,000
7,963,000
-%

1–10 of 44

Are Funds Buying or Selling KRYS?

Are funds buying KRYS calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own KRYS
No. of Funds

Unveiling Krystal Biotech Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
avoro capital advisors llc
9.1%
2,565,555
SC 13G/A
Feb 14, 2024
redmile group, llc
6.1%
1,733,189
SC 13G/A
Feb 13, 2024
vanguard group inc
8.64%
2,435,774
SC 13G
Feb 12, 2024
fmr llc
-
0
SC 13G/A
Feb 09, 2024
fmr llc
-
0
SC 13G/A
Jan 29, 2024
blackrock inc.
6.4%
1,809,377
SC 13G/A
May 10, 2023
fmr llc
-
0
SC 13G/A
Feb 14, 2023
avoro capital advisors llc
5.5%
1,410,000
SC 13G
Feb 14, 2023
redmile group, llc
7.4%
1,896,645
SC 13G/A
Feb 14, 2023
point72 asset management, l.p.
2.2%
556,252
SC 13G/A

Recent SEC filings of Krystal Biotech Inc

View All Filings
Date Filed Form Type Document
Mar 11, 2024
144
Notice of Insider Sale Intent
Mar 11, 2024
144
Notice of Insider Sale Intent
Mar 11, 2024
4
Insider Trading
Mar 11, 2024
4
Insider Trading
Mar 01, 2024
4
Insider Trading
Mar 01, 2024
4
Insider Trading
Mar 01, 2024
4
Insider Trading
Mar 01, 2024
4
Insider Trading
Feb 28, 2024
4
Insider Trading
Feb 28, 2024
144
Notice of Insider Sale Intent

Peers (Alternatives to Krystal Biotech Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
42.3B
6.8B
19.31% -24.90%
-8.96
6.17
-64.45% -156.37%
22.4B
152.6K
-0.77% 465779.94%
-2.4K
146.8K
- -9.98%
19.4B
1.8B
-0.33% -18.28%
-44.17
10.64
76.23% 61.08%
16.7B
2.4B
-4.10% -7.32%
99.73
6.91
15.42% 18.43%
12.8B
3.7B
-1.69% -18.94%
21.46
3.47
8.87% 75.42%
MID-CAP
7.1B
396.6M
-19.47% -8.81%
-13.34
17.78
425.83% 18.94%
5.4B
-
-20.51% 118.30%
-8.31
60.35
54.84% -34.79%
3.8B
270.6M
-13.09% 29.37%
-15.68
13.86
440.80% -27.84%
3.6B
240.7M
-7.70% 7.49%
-11.98
14.77
-1.03% -92.09%
3.0B
726.4M
-28.51% -9.28%
-48.93
4.13
40.45% 71.62%
SMALL-CAP
1.9B
398.2M
12.36% 9.77%
26.85
4.82
85.90% -14.05%
678.8M
983.7M
12.98% -18.87%
-1.25
0.69
-50.36% 17.16%
373.2M
881.7K
51.26% 463.55%
-8.37
466.16
-77.61% -5.33%
304.5M
4.9M
46.53% -11.16%
-2.25
62.57
-54.97% 51.72%
11.8M
2.1M
-13.49% -43.81%
-0.43
2.14
-13.45% 66.37%

Krystal Biotech Inc News

Latest updates
Defense World • 23 Mar 2024 • 05:53 am
InvestorsObserver • 22 Mar 2024 • 04:33 pm
CNN • 12 Mar 2024 • 05:36 am
Zacks Investment Research • 08 Mar 2024 • 05:24 pm
Yahoo Finance • 08 Mar 2024 • 08:00 am
Yahoo Finance • 08 Mar 2024 • 08:00 am
Markets Insider • 27 Feb 2024 • 08:00 am
Zacks Investment Research • 26 Feb 2024 • 08:00 am
Seeking Alpha • 20 Feb 2024 • 08:00 am

Krystal Biotech Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42018Q32018Q2
Revenue392.6%42,143,0008,556,000-------3,0002,000
Operating Expenses12.9%39,005,50034,549,00038,048,00048,823,00034,770,50031,451,00028,753,00050,222,00021,876,5002,972,0002,449,000
  S&GA Expenses4.5%24,764,50023,697,00025,904,00024,035,00024,029,50019,935,00017,863,00015,908,00012,867,5001,058,000924,000
  R&D Expenses7.0%11,370,00010,629,00012,144,00012,288,00010,741,00011,516,00010,890,0009,314,0009,009,0001,914,0001,525,000
EBITDA Margin-0.35----------
Interest Expenses------------
EBT Margin-0.25----------
Net Income-89.2%8,692,00080,747,000-33,210,000-45,297,000-32,052,000-29,850,000-28,108,000-49,965,000-21,806,000-2,755,000-2,276,000
Net Income Margin-0.22----------
Free Cashflow60.5%-9,079,000-23,007,000-36,980,000-31,537,000-27,546,000-33,744,000-59,574,000-32,684,000-61,783,000--
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets3.5%818790684532558576601617626451444443311311318205209214205116116
  Current Assets1.0%588582484355384398429438442346370406275288299188196204196108113
    Cash Equivalents-4.0%35837327614116218621926934128733040226828229218018819518798.00104
  Inventory32.3%7.005.00-------------------
  Net PPE-1.7%16116416416316215815113711279.0045.0034.0031.0018.0013.0010.008.007.006.004.003.00
Liabilities15.4%40.0034.0031.0042.0036.0036.0042.0068.0033.0043.0025.0012.0019.0010.008.007.006.007.007.006.003.00
  Current Liabilities20.0%33.0028.0024.0035.0029.0028.0034.0060.0026.0036.0018.009.0015.007.006.004.003.004.004.003.003.00
Shareholder's Equity3.0%779756653490522541559549594408419431292302310198203208198109113
  Retained Earnings3.1%-269-278-359-326-280-248-218-190-140-118-103-87.03-71.21-60.80-51.22-44.39-39.05-33.69-29.42-24.07-19.96
  Additional Paid-In Capital1.3%1,0481,0351,013816804791780741735527522518363363361243242241228134133
Shares Outstanding0.1%28.0028.0028.0026.0026.0026.0025.0025.0022.0022.0022.0021.00---------
Float---2,800---1,400---1,200---595---454--
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations65.9%-7,232-21,226-34,190-26,156-22,329-19,688-43,059-15,493-20,900-7,255-10,129-9,654-8,024-6,778-5,054-6,227-7,000-4,266-4,209-3,215-3,518
  Share Based Compensation18.5%9,8538,31211,33110,4379,5529,0598,1896,4305,1453,6664,1952,3135701,356807539323278325313302
Cashflow From Investing-109.7%-10,160105,192-15,9573,563-5,208-14,743-38,224-55,908-126,540-37,166-62,317-747-6,217-2,697-962-1,305-591-682-1,236-2,482-3,767
Cashflow From Financing-80.4%2,61913,388185,2691,4743,0692,12030,700-542202,0721,508-199144,304141166117,46924329913,16794,01940.0064,288

KRYS Income Statement

2023-12-31
Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($)
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Statement of Comprehensive Income [Abstract]   
Revenue from Contract with Customer, Product and Service [Extensible Enumeration]Product [Member]Product [Member]Product [Member]
Product revenue, net$ 50,699,000$ 0$ 0
Expenses   
Cost, Product and Service [Extensible Enumeration]Product [Member]Product [Member]Product [Member]
Cost of goods sold$ 3,094,000$ 0$ 0
Research and development46,431,00042,461,00027,884,000
Selling, general and administrative98,401,00077,735,00040,391,000
Litigation settlement12,500,00025,000,0000
Total operating expenses160,426,000145,196,00068,275,000
Loss from operations(109,727,000)(145,196,000)(68,275,000)
Other income (expense)   
Gain from sale of priority review voucher100,000,00000
Interest and other income, net22,624,0005,221,000197,000
Interest expense00(1,492,000)
Income (loss) before income taxes12,897,000(139,975,000)(69,570,000)
Income tax expense(1,965,000)00
Net income (loss)10,932,000(139,975,000)(69,570,000)
Unrealized income (loss) on available-for-sale securities and other[1]1,366,000(565,000)(169,000)
Comprehensive income (loss)$ 12,298,000$ (140,540,000)$ (69,739,000)
Net income (loss) per common share:   
Net income (loss) per common share: basic (in usd per share)$ 0.40$ (5.49)$ (3.13)
Net income (loss) per common share: diluted (in usd per share)$ 0.39$ (5.49)$ (3.13)
Weighted-average common shares outstanding:   
Weighted-average common shares outstanding: basic (in shares)27,154,19025,491,72122,196,846
Weighted-average common shares outstanding: diluted (in shares)27,751,80925,491,72122,196,846
[1]Includes foreign currency translation losses of $66 thousand and $78 thousand, and a gain of $7 thousand for the years ended December 31, 2023, 2022, and 2021, respectively.

KRYS Balance Sheet

2023-12-31
Consolidated Balance Sheets - USD ($)
Dec. 31, 2023
Dec. 31, 2022
Current assets  
Cash and cash equivalents$ 358,328,000$ 161,900,000
Short-term investments173,850,000217,271,000
Accounts receivable, net42,040,0000
Inventory6,985,0000
Prepaid expenses and other current assets6,706,0004,608,000
Total current assets587,909,000383,779,000
Property and equipment, net161,202,000161,684,000
Long-term investments61,954,0004,621,000
Right-of-use assets7,027,0008,042,000
Other non-current assets263,000324,000
Total assets818,355,000558,450,000
Current liabilities  
Accounts payable4,132,0003,981,000
Current portion of lease liability1,474,0001,561,000
Accrued expenses and other current liabilities27,488,00023,305,000
Total current liabilities33,094,00028,847,000
Lease liability6,620,0007,372,000
Total liabilities39,714,00036,219,000
Commitments and contingencies (Note 7)
Stockholders' equity  
Common stock; $0.00001 par value; 80,000,000 shares authorized at December 31, 2023 and 2022; 28,236,673 and 25,763,743 shares issued and outstanding at December 31, 2023 and 2022, respectively00
Additional paid-in capital1,047,830,000803,718,000
Accumulated other comprehensive gain (loss)638,000(728,000)
Accumulated deficit(269,827,000)(280,759,000)
Total stockholders' equity778,641,000522,231,000
Total liabilities and stockholders' equity$ 818,355,000$ 558,450,000
KRYS
Krystal Biotech, Inc., a biotechnology company, develops and commercializes genetic medicines for patients with rare diseases in the United States. It develops beremagene geperpavec (B-VEC) for dystrophic epidermolysis bullosa; KB105 for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for netherton syndrome; and KB407 for Cystic Fibrosis. The company also develops KB408 for Alpha-1 antitrypsin deficiency; and KB301 for aesthetic skin conditions. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
 CEO
 WEBSITEwww.krystalbio.com
 EMPLOYEES210

Krystal Biotech Inc Frequently Asked Questions


What is the ticker symbol for Krystal Biotech Inc? What does KRYS stand for in stocks?

KRYS is the stock ticker symbol of Krystal Biotech Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Krystal Biotech Inc (KRYS)?

As of Wed Mar 27 2024, market cap of Krystal Biotech Inc is 5.01 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of KRYS stock?

You can check KRYS's fair value in chart for subscribers.

What is the fair value of KRYS stock?

You can check KRYS's fair value in chart for subscribers. The fair value of Krystal Biotech Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Krystal Biotech Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for KRYS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Krystal Biotech Inc a good stock to buy?

The fair value guage provides a quick view whether KRYS is over valued or under valued. Whether Krystal Biotech Inc is cheap or expensive depends on the assumptions which impact Krystal Biotech Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for KRYS.

What is Krystal Biotech Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Mar 27 2024, KRYS's PE ratio (Price to Earnings) is 458.6 and Price to Sales (PS) ratio is 98.89. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. KRYS PE ratio will change depending on the future growth rate expectations of investors.